Comparative Pharmacology
Head-to-head clinical analysis: ORETICYL 25 versus VASERETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORETICYL 25 versus VASERETIC.
ORETICYL 25 vs VASERETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive NaCl cotransporter, increasing excretion of sodium, chloride, and water. Deserpidine depletes catecholamines from peripheral sympathetic nerve endings by binding to the vesicular monoamine transporter, reducing vascular resistance and heart rate.
Vaseretic is a combination of enalapril maleate (an angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (a thiazide diuretic). Enalapril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and chloride excretion by inhibiting the Na+-Cl- symporter in the distal convoluted tubule, leading to diuresis and vasodilation.
Hydrochlorothiazide 25 mg orally once daily; may increase to 50 mg daily if needed.
One tablet (10 mg enalapril maleate/25 mg hydrochlorothiazide) orally once daily; may increase to 2 tablets daily if needed.
None Documented
None Documented
2.5 hours; in renal impairment may extend to 8–15 hours.
Enalaprilat: 35–38 hours (terminal). Clinically, effective half-life ~11 hours. Prolonged in renal impairment (CrCl <30 mL/min: up to 60 hours).
Primarily renal (95% unchanged); minimal biliary (<5%).
Renal: 60% (enalaprilat); biliary/fecal: 33% (enalaprilat). Unchanged enalapril: <5% in urine.
Category C
Category C
Diuretic Combination
ACE Inhibitor/Diuretic Combination